ASH 2020 | Real-world data on outcomes of t(11;14) multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses an investigation into t(11;14) multiple myeloma using real-world data. Patient and disease characteristics were compared between t(11;14) positive and t(11;14) negative patients, as well as other genetic subgroups. The study found that t(11;14) positive patients had worse progression-free survival (PFS) and overall survival (OS) compared to t(11;14) negative patients despite novel targeted therapeutics. Additionally, t(11;14) worsened prognosis in myeloma with del(17p), acting as a high-risk translocation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Luciano Costa, MD, PhD, has received research funding from Amgen and Janssen; and has received honoraria from Amgen, Janssen, BMS and Sanofi.
